The impact of policy interventions to promote the uptake of biosimilar medicines in Belgium: a nationwide interrupted time series analysis

[11] Brodszky V(2015)Interrupted time series analysis in drug utilization research is increasing: systematic review and recommendations J Clin Epidemiol 27 76-356

[12] Baji P(2017)Interrupted time series regression for the evaluation of public health interventions: a tutorial Int J Epidemiol 5 739-285

[13] Rencz F(2021)Interrupted time series analysis using autoregressive integrated moving average (ARIMA) models: a guide for evaluating large-scale health interventions BMC Med Res Methodol 33 353-17

[14] Péntek M(2012)How to do (or not to do) … Assessing the impact of a policy change with routine longitudinal data Health Policy Plan 5 1307315-404

[15] Dutta B(1998)Time series analysis using autoregressive integrated moving average (ARIMA) models Acad Emerg Med 14 280-1418

[16] Huys I(2019)Biosimilars: a value proposition BioDrugs 21 9-1330

[17] Vulto AG(2017)Supply-side and demand-side policies for biosimilars: an overview in 10 European member states J Mark access Heal policy 373 117-808

[18] Simoens S(2020)Biosimilars in oncology—Part I: The principles of biosimilars Belgian J Med Oncol. 14 397-1172

[19] Walsh G(2022)Biosimilar use and switching in Belgium: avenues for integrated policy making Front Pharmacol 32 1408-561

[20] Walsh E(2021)A health economic guide to market access of biosimilars Expert Opin Biol Ther 70 557-1323

[11] Brodszky V(2015)Interrupted time series analysis in drug utilization research is increasing: systematic review and recommendations J Clin Epidemiol 27 76-356

[12] Baji P(2017)Interrupted time series regression for the evaluation of public health interventions: a tutorial Int J Epidemiol 5 739-285

[13] Rencz F(2021)Interrupted time series analysis using autoregressive integrated moving average (ARIMA) models: a guide for evaluating large-scale health interventions BMC Med Res Methodol 33 353-17

[14] Péntek M(2012)How to do (or not to do) … Assessing the impact of a policy change with routine longitudinal data Health Policy Plan 5 1307315-404

[15] Dutta B(1998)Time series analysis using autoregressive integrated moving average (ARIMA) models Acad Emerg Med 14 280-1418

[16] Huys I(2019)Biosimilars: a value proposition BioDrugs 21 9-1330

[17] Vulto AG(2017)Supply-side and demand-side policies for biosimilars: an overview in 10 European member states J Mark access Heal policy 373 117-808

[18] Simoens S(2020)Biosimilars in oncology—Part I: The principles of biosimilars Belgian J Med Oncol. 14 397-1172

[19] Walsh G(2022)Biosimilar use and switching in Belgium: avenues for integrated policy making Front Pharmacol 32 1408-561

[20] Walsh E(2021)A health economic guide to market access of biosimilars Expert Opin Biol Ther 70 557-1323